Kiniksa Pharmaceuticals International, plc GAAP EPS of $0.56 beats by $0.21, revenue of $286M beats by $25.39M

Kiniksa tops Q3 earnings and revenue estimates, raises 2026 ARCALYST revenue guidance, and stays cash flow positive.